@article{Pearce:2023:10.1016/s2665-9913(23)00160-1,
author = {Pearce, FA and Lim, SH and Bythell, M and Lanyon, P and Hogg, R and Taylor, A and Powter, G and Cooke, GS and Ward, H and Chilcot, J and Thomas, H and Mumford, L and McAdoo, SP and Pettigrew, GJ and Lightstone, L and Willicombe, M},
doi = {10.1016/s2665-9913(23)00160-1},
journal = {The Lancet Rheumatology},
pages = {e461--e473},
title = {Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY},
url = {http://dx.doi.org/10.1016/s2665-9913(23)00160-1},
volume = {5},
year = {2023}
}

Download

TY  - JOUR
AB  - BackgroundIn the UK, additional COVID-19 vaccine booster doses and treatments are offered to people who are immunosuppressed to protect against severe COVID-19, but how best to choose the individuals that receive these vaccine booster doses and treatments is unclear. We investigated the association between seropositivity to SARS-CoV-2 spike protein with demographic, disease, and treatment-related characteristics after at least three COVID-19 vaccines in three cohorts of people who are immunosuppressed.MethodsIn a cross-sectional study using UK national disease registries, we identified, contacted, and recruited recipients of solid organ transplants, participants with rare autoimmune rheumatic diseases, and participants with lymphoid malignancies who were 18 years or older, resident in the UK, and who had received at least three doses of a COVID-19 vaccine. The study was open to recruitment from Dec 7, 2021, to June 26, 2022. Participants received a lateral flow immunoassay test for SARS-CoV-2 spike antibodies to complete at home, and an online questionnaire. Multivariable logistic regression was used to estimate the mutually adjusted odds of seropositivity against each characteristic.FindingsBetween Feb 14 and June 26, 2022, we screened 101 972 people (98 725 invited, 3247 self-enrolled) and recruited 28 411 (27·9%) to the study. 23 036 (81·1%) recruited individuals provided serological data. Of these, 9927 (43·1%) were recipients of solid organ transplants, 6516 (28·3%) had rare autoimmune rheumatic diseases, and 6593 (28·6%) had lymphoid malignancies. 10 485 (45·5%) participants were men and 12 535 (54·4%) were women (gender was not reported for 16 [<0·1%] participants), and 21661 (94·0%) participants were of White ethnicity. The median age of participants with solid organ transplants was 60 years (SD 50–67), with rare autoimmune rheumatic diseases was
AU  - Pearce,FA
AU  - Lim,SH
AU  - Bythell,M
AU  - Lanyon,P
AU  - Hogg,R
AU  - Taylor,A
AU  - Powter,G
AU  - Cooke,GS
AU  - Ward,H
AU  - Chilcot,J
AU  - Thomas,H
AU  - Mumford,L
AU  - McAdoo,SP
AU  - Pettigrew,GJ
AU  - Lightstone,L
AU  - Willicombe,M
DO  - 10.1016/s2665-9913(23)00160-1
EP  - 473
PY  - 2023///
SN  - 2665-9913
SP  - 461
TI  - Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY
T2  - The Lancet Rheumatology
UR  - http://dx.doi.org/10.1016/s2665-9913(23)00160-1
UR  - http://hdl.handle.net/10044/1/106088
VL  - 5
ER  - 

Download